BIO | Jotup

EQS-News: Lenzing presents innovative concept combining sustainable glacier protection and circularity for textiles

Retrieved on:

星期三, 四月 10, 2024

Lenzing – The Lenzing Group, a leading supplier of regenerated cellulose for the textile and nonwovens industries, has created a unique, innovative concept that contributes to the sustainable protection of our glaciers while inspiring collective action for sustainable practices and a circular economy in the nonwovens and textile value chain.

Key Points:

Lenzing – The Lenzing Group, a leading supplier of regenerated cellulose for the textile and nonwovens industries, has created a unique, innovative concept that contributes to the sustainable protection of our glaciers while inspiring collective action for sustainable practices and a circular economy in the nonwovens and textile value chain.
[2]
The covering of a small area with the new material made from LENZING™ fibers was tested for the first time during a field test on the Stubai Glacier.
This was confirmed in a study conducted by the University of Innsbruck and the Austrian glacier lift operators on the Stubai Glacier in Tyrol (Austria).
Lenzing takes this pioneering innovation project as an opportunity to inspire collaborative action towards sustainable practices and circularity in the textile value chain.

Predictive Oncology Reports Year End 2023 Financial Results and Provides Business Update

Retrieved on:

星期四, 三月 28, 2024

The company reported a net loss of approximately $14 million on total revenue of approximately $1.8 million for the year ended December 31, 2023.

Key Points:

The company reported a net loss of approximately $14 million on total revenue of approximately $1.8 million for the year ended December 31, 2023.
“Perhaps most notably, we announced last quarter that we successfully delivered the results of our first campaign with Cancer Research Horizons.
Revenues for the years ended December 31, 2023, and December 31, 2022, were primarily derived from its Eagan operating segment.
Conference call and webcast details:
Predictive Oncology management will host an investor conference call and webcast on Monday, April 1st, at 8:30am EDT.

Tonix Pharmaceuticals Announces Presentation at BIO-Europe Spring

Retrieved on:

星期二, 三月 12, 2024

Tonix Pharmaceuticals, BIO

CHATHAM, N.J., March 12, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals, will present at the 2024 BIO-Europe Spring Convention being held March 18-20, 2024 in Barcelona, Spain. The presentation will take place on Tuesday, March 19, 2024 at 10:45 a.m. CET in Room 133/134 of the CCIB Barcelona.

Key Points:

CHATHAM, N.J., March 12, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals, will present at the 2024 BIO-Europe Spring Convention being held March 18-20, 2024 in Barcelona, Spain.
The presentation will take place on Tuesday, March 19, 2024 at 10:45 a.m. CET in Room 133/134 of the CCIB Barcelona.
To schedule a meeting with the Company’s management at the convention, please submit a meeting request through the BIO One-on-One Partnering™ system or contact [email protected] .

ELIQUENT Life Sciences Announces Appointment of Former FDA Senior Officials

Retrieved on:

星期四, 三月 21, 2024

ELIQUENT Life Sciences, a global regulatory consulting firm for the life sciences industry, today announced the appointment of John Taylor as head of the firm’s Quality & Compliance Practice and Michele Dougherty as head of the firm’s Regulatory Affairs Practice.

Key Points:

ELIQUENT Life Sciences, a global regulatory consulting firm for the life sciences industry, today announced the appointment of John Taylor as head of the firm’s Quality & Compliance Practice and Michele Dougherty as head of the firm’s Regulatory Affairs Practice.
View the full release here: https://www.businesswire.com/news/home/20240321127987/en/
John Taylor, Head of Quality & Compliance Practice, ELIQUENT Life Sciences (Photo: Business Wire)
ELIQUENT’s integrated suite of services deliver the answers and solutions that global life sciences innovators need to gain and maintain market authorization for their products.
Most recently, John served for 10-years as President and Principal of Compliance & Regulatory Affairs at Greenleaf Health, a legacy brand of ELIQUENT Life Sciences.
A 10-year veteran of FDA, Michele’s career includes more than 15-years of regulatory experience across the product quality lifecycle, including her most recent role as President of DataRevive, a legacy brand of ELIQUENT Life Sciences.

BIO KOREA 2024: Registration Open for Business Partnering

Retrieved on:

星期一, 三月 11, 2024

Technology, Research, Business, Professional Services, Biotechnology, Health, Pharmaceutical, Science, Artificial Intelligence, Online, COVID-19, BIO, OPA, FCA, Regenerative medicine, Labcorp, Business partnering, Yuhan

BIO KOREA 2024 , jointly held by the Korea Health Industry Development Institute (KHIDI, President: Cha Soon-do) and Chungcheongbuk-do (Governor: Kim Young-hwan), has commenced its registration for Business Partnering on March 4, 2024 (Mon.).

Key Points:

BIO KOREA 2024 , jointly held by the Korea Health Industry Development Institute (KHIDI, President: Cha Soon-do) and Chungcheongbuk-do (Governor: Kim Young-hwan), has commenced its registration for Business Partnering on March 4, 2024 (Mon.).
Business Partnering, one of the major programs at BIO KOREA, provides opportunities for one-on-one meetings between companies at home and abroad, alongside pertinent institutions within the BioHealth sector.
This year, the Business Partnering Center will be expanded to provide more opportunities for participating companies to make business connections.
Throughout the three-day event from May 8 (Wed.) to May 10 (Fri.), the Business Partnering will unfold both online and offline on the sidelines of BIO KOREA 2024.

Hyosung TNC Invests $1 Billion in Future "Bio" Business

Retrieved on:

星期一, 四月 1, 2024

Chairman Hyun-Joon Cho states, "The bio business will become a core pillar of Hyosung for the next 100 years.

Key Points:

Chairman Hyun-Joon Cho states, "The bio business will become a core pillar of Hyosung for the next 100 years.
SEOUL, South Korea, April 1, 2024 /PRNewswire/ -- Hyun-Joon Cho, chairman of Hyosung announces major investment in the bio business, embarking on future new business ventures.
Hyosung TNC plans to proactively respond to the global materials market's reorganization around sustainable products by investing $1 billion to establish multiple Bio-BDO production plants capable of producing 200,000 tons annually.
From Raw Material to Fiber, Hyosung TNC Establishes the World's First Fully-Integrated Production System for Bio-Spandex
With this investment, Hyosung TNC has secured the largest bio-spandex factory in Vietnam.

Hyosung TNC Invests $1 Billion in Future "Bio" Business

Retrieved on:

星期一, 四月 1, 2024

Chairman Hyun-Joon Cho states, "The bio business will become a core pillar of Hyosung for the next 100 years.

Key Points:

Chairman Hyun-Joon Cho states, "The bio business will become a core pillar of Hyosung for the next 100 years.
SEOUL, South Korea, March 31, 2024 /PRNewswire/ -- Hyun-Joon Cho, chairman of Hyosung announces major investment in the bio business, embarking on future new business ventures.
Hyosung TNC plans to proactively respond to the global materials market's reorganization around sustainable products by investing $1 billion to establish multiple Bio-BDO production plants capable of producing 200,000 tons annually.
From Raw Material to Fiber, Hyosung TNC Establishes the World's First Fully-Integrated Production System for Bio-Spandex
With this investment, Hyosung TNC has secured the largest bio-spandex factory in Vietnam.

AEOVIAN PHARMACEUTICALS DOSES FIRST PARTICIPANTS IN PHASE 1 CLINICAL TRIAL, STRENGTHENS LEADERSHIP TEAM AND RAISES ADDITIONAL $50 MILLION FINANCING

Retrieved on:

星期四, 三月 28, 2024

BERKELEY, Calif., March 28, 2024 /PRNewswire/ -- Aeovian Pharmaceuticals, a clinical-stage biopharmaceutical company developing novel and highly selective therapeutics that potently inhibit the mTORC1 pathway, today announced that it has dosed the first cohort of participants in a Phase 1 clinical trial for its lead development candidate AV078, a first-in-class CNS penetrant selective mTORC1 inhibitor. Supporting this transition into the clinic, the company has also expanded its leadership team with the appointment of seasoned industry veterans William Greene, M.D., Chief Investment Officer at Hevolution, and Justin Gover, former Chief Executive Officer of GW Pharmaceuticals, to the company's Board of Directors, and appointed Micah Zajic as Chief Financial Officer. The company also recently completed a $50 million financing, led by Hevolution.

Key Points:

Aeovian has assembled a compelling platform for the development of selective mTORC1 inhibitors," said Dr. Greene, CIO at Hevolution.
In the $50M financing, Hevolution was joined by existing investors Apollo Health Ventures, Sofinnova Investments, venBio, Evotec and b2venture.
This financing will support the completion of the Phase 1 clinical trial in healthy volunteers and prepare for the start of a subsequent Phase 2 clinical trial in adult and pediatric patients with TSC refractory epilepsy.
As CEO, he built and led Iconic Therapeutics through discovery, clinical development, and venture financing, which culminated in a successful sale of the company.

Pacylex to Meet with Investors at Bio CEO Conference (BCIC) in New York City, February 26-27, 2024

Retrieved on:

星期五, 二月 23, 2024

Bone marrow, AML, NHL, BIO, Conference, Patient, Acute myeloid leukemia, Colorectal cancer, Cancer, Pharmaceutical industry

The company's lead candidate, zelenirstat, is a first-in-class, orally bioavailable small molecule myristoylation inhibitor, a new mechanism of action for cancer treatment.

Key Points:

The company's lead candidate, zelenirstat, is a first-in-class, orally bioavailable small molecule myristoylation inhibitor, a new mechanism of action for cancer treatment.
Zelenirstat is currently being studied in patients who have failed available treatments (refractory or relapsed; r/r).
If you are attending BIO CEO & Investors, we would like to talk to you about investing in Pacylex and zelenirstat, a first-in-class oral cancer drug in Phase 2.
Zelenirstat has a great safety profile and evidence of benefit in refractory patients with solid and liquid tumors.

Aerovate Therapeutics Board of Directors Appoints Habib Dable as Board Chair

Retrieved on:

星期三, 三月 6, 2024

Biotechnology Innovation Organization, Merck, Drug development, BIO, Sale, PAH, Merck & Co., Chairperson, Therapy, Bayer, Patient, Pharmaceutical industry

WALTHAM, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease, today announced that its Board of Directors has elected current Board member, Habib Dable, as Chair of the Board.

Key Points:

WALTHAM, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease, today announced that its Board of Directors has elected current Board member, Habib Dable, as Chair of the Board.
Mr. Dable succeeds Mark Iwicki, who will continue to serve on the Board.
“We are pleased to have Habib take on the role of Chair of the Board,” said Tim Noyes, Chief Executive Officer of Aerovate Therapeutics.
I would also like to thank Mark for his significant contributions and commitment to Aerovate, and I look forward to continuing to work together.”
“I am honored to assume the role of Board Chair for Aerovate during this exciting time for the company,” said Mr. Dable.